CAR-T cell therapy for multiple myeloma

Abstract

 Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has been shown to be highly effective in B-cell leukemias and lymphomas. Many researchers are currently trying to develop CAR-T cells for various types of cancer. B-cell maturation antigen (BCMA) has been shown to be an excellent target for multiple myeloma (MM). However, MM remains difficult to cure, and many researchers are trying to identify additional target molecules. Recently, the efficacy of CAR-T cells targeting GRPC5 was reported. We also reported that activated integrin β7 is a good target for CAR-T cell therapy against MM, and clinical trials are currently underway.